97 related articles for article (PubMed ID: 16477670)
1. Comparison of promoter region constructs for in vivo intramuscular expression.
Fabre EE; Bigey P; Orsini C; Scherman D
J Gene Med; 2006 May; 8(5):636-45. PubMed ID: 16477670
[TBL] [Abstract][Full Text] [Related]
2. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
3. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
[TBL] [Abstract][Full Text] [Related]
4. The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice.
Larochelle N; Oualikene W; Dunant P; Massie B; Karpati G; Nalbantoglu J; Lochmuller H
Biochem Biophys Res Commun; 2002 Apr; 292(3):626-31. PubMed ID: 11922612
[TBL] [Abstract][Full Text] [Related]
5. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems.
Li S; MacLaughlin FC; Fewell JG; Li Y; Mehta V; French MF; Nordstrom JL; Coleman M; Belagali NS; Schwartz RJ; Smith LC
Gene Ther; 1999 Dec; 6(12):2005-11. PubMed ID: 10637452
[TBL] [Abstract][Full Text] [Related]
6. Sustained expression after nonviral ocular gene transfer using mammalian promoters.
Kachi S; Esumi N; Zack DJ; Campochiaro PA
Gene Ther; 2006 May; 13(9):798-804. PubMed ID: 16467860
[TBL] [Abstract][Full Text] [Related]
7. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
8. Construction and analysis of compact muscle-specific promoters for AAV vectors.
Wang B; Li J; Fu FH; Chen C; Zhu X; Zhou L; Jiang X; Xiao X
Gene Ther; 2008 Nov; 15(22):1489-99. PubMed ID: 18563184
[TBL] [Abstract][Full Text] [Related]
9. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
10. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
11. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer.
Larochelle N; Lochmüller H; Zhao J; Jani A; Hallauer P; Hastings KE; Massie B; Prescott S; Petrof BJ; Karpati G; Nalbantoglu J
Gene Ther; 1997 May; 4(5):465-72. PubMed ID: 9274724
[TBL] [Abstract][Full Text] [Related]
12. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.
Cao B; Bruder J; Kovesdi I; Huard J
Gene Ther; 2004 Sep; 11(17):1321-30. PubMed ID: 15175641
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral-mediated skeletal muscle transcriptional targeting using chimeric tissue-specific promoters.
Frauli M; Ribault S; Neuville P; Augé F; Calenda V
Med Sci Monit; 2003 Feb; 9(2):BR78-84. PubMed ID: 12601283
[TBL] [Abstract][Full Text] [Related]
14. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery.
Wooddell CI; Reppen T; Wolff JA; Herweijer H
J Gene Med; 2008 May; 10(5):551-63. PubMed ID: 18330848
[TBL] [Abstract][Full Text] [Related]
15. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
16. In vivo electroporation and ubiquitin promoter--a protocol for sustained gene expression in the lung.
Gazdhar A; Bilici M; Pierog J; Ayuni EL; Gugger M; Wetterwald A; Cecchini M; Schmid RA
J Gene Med; 2006 Jul; 8(7):910-8. PubMed ID: 16685743
[TBL] [Abstract][Full Text] [Related]
17. Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle.
Nalbantoglu J; Larochelle N; Wolf E; Karpati G; Lochmuller H; Holland PC
J Virol; 2001 May; 75(9):4276-82. PubMed ID: 11287577
[TBL] [Abstract][Full Text] [Related]
18. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
19. A CMV-actin-globin hybrid promoter improves adeno-associated viral vector gene expression in the arterial wall in vivo.
Nitta Y; Kawamoto S; Halbert C; Iwata A; Miller AD; Miyazaki J; Allen MD
J Gene Med; 2005 Oct; 7(10):1348-55. PubMed ID: 15945122
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
